secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001104659-21-100755
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q2 revenue up 64% to $142M; guides FY2021 revenue to $600-620M
---------------------------------------------------------------------

- Product revenue $137.2M, +70.7% YoY; processed 375,700 tests, +60.5%.
- Net loss $116.0M ($1.32/share) vs $59.6M ($0.75) a year ago.
- Raised 2021 revenue guidance to $600-620M from $550-575M (second increase).
- Completed $551.2M net follow-on equity offering in July 2021.
- CMS awarded ADLT status for Signatera MRD test; GSK phase III trial announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465921100755/0001104659-21-100755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465921100755/tm2124237d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-100755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer